Travere Therapeutics (NASDAQ:TVTX) Shares Down 6.2% – Here’s What Happened

Travere Therapeutics, Inc. (NASDAQ:TVTX)’s share price traded down 6.2% during trading on Monday . The company traded as low as $32.40 and last traded at $32.4520. 447,666 shares were traded during mid-day trading, a decline of 79% from the average session volume of 2,136,920 shares. The stock had previously closed at $34.58.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Canaccord Genuity reiterated/issued a Buy on TVTX, which supports a constructive view on the company’s longer‑term commercial potential. Travere Therapeutics (TVTX) Receives a Buy from Canaccord Genuity
• Neutral Sentiment: Management presented at the J.P. Morgan Healthcare Conference (transcript available), providing investor access to strategy and data but no immediate regulatory reversal. Travere Therapeutics, Inc. (TVTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Trading in TVTX was temporarily halted ahead of the company’s disclosure, a procedural move that concentrated volume and volatility when trading resumed.
• Negative Sentiment: FDA extended the review of the FILSPARI sNDA, moving the PDUFA action date to April 13, 2026 — the company said the extension follows requests for further characterization of clinical benefit. This regulatory delay is the main proximate cause of downward pressure. Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
• Negative Sentiment: Multiple law firms (Holzer & Holzer; Robbins Geller; Block & Leviton, among others) have opened shareholder investigations into possible securities claims tied to the FDA news and disclosures—this raises potential litigation risk and further investor uncertainty. INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC
• Negative Sentiment: Unusually large put-option activity and heavy intraday selling amplified the move lower, signaling short‑term bearish positioning by traders. Options Bears Eye Plummeting Biotech Stock

Wall Street Analysts Forecast Growth

A number of research analysts have commented on TVTX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $47.00 price target on shares of Travere Therapeutics in a research report on Friday, November 28th. TD Cowen upped their price objective on Travere Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Citigroup increased their price objective on Travere Therapeutics from $34.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Piper Sandler boosted their target price on Travere Therapeutics from $26.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Thirteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.86.

Travere Therapeutics Stock Down 0.6%

The company has a debt-to-equity ratio of 4.23, a quick ratio of 2.71 and a current ratio of 2.75. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -27.29, a PEG ratio of 1.03 and a beta of 0.85. The firm has a fifty day moving average price of $35.52 and a 200 day moving average price of $26.29.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, October 30th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.59. The company had revenue of $164.86 million during the quarter, compared to the consensus estimate of $106.09 million. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.Travere Therapeutics’s quarterly revenue was up 162.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.70) earnings per share. As a group, sell-side analysts expect that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Insider Activity at Travere Therapeutics

In other Travere Therapeutics news, Director Timothy Coughlin sold 18,000 shares of the business’s stock in a transaction on Friday, October 31st. The stock was sold at an average price of $35.03, for a total transaction of $630,540.00. Following the sale, the director directly owned 55,500 shares in the company, valued at approximately $1,944,165. The trade was a 24.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christopher R. Cline sold 20,000 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $35.01, for a total value of $700,200.00. Following the completion of the sale, the chief financial officer directly owned 92,083 shares in the company, valued at $3,223,825.83. This trade represents a 17.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 323,226 shares of company stock valued at $11,290,656 in the last ninety days. Company insiders own 4.19% of the company’s stock.

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TVTX. Capital Fund Management S.A. acquired a new position in shares of Travere Therapeutics during the 2nd quarter worth approximately $1,501,000. Squarepoint Ops LLC raised its stake in Travere Therapeutics by 98.7% in the 2nd quarter. Squarepoint Ops LLC now owns 479,394 shares of the company’s stock valued at $7,095,000 after purchasing an additional 238,070 shares during the last quarter. Voya Investment Management LLC lifted its holdings in Travere Therapeutics by 16.2% in the 3rd quarter. Voya Investment Management LLC now owns 194,854 shares of the company’s stock valued at $4,657,000 after purchasing an additional 27,133 shares in the last quarter. Y Intercept Hong Kong Ltd boosted its stake in shares of Travere Therapeutics by 343.7% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 68,000 shares of the company’s stock worth $1,006,000 after purchasing an additional 52,675 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. purchased a new stake in shares of Travere Therapeutics during the second quarter worth about $2,486,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.